{
    "organizations": [],
    "uuid": "1841357a5af3f5d9883e107e2e456693c35c9f18",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sirenas-enters-into-multi-target-c/brief-sirenas-enters-into-multi-target-collaboration-with-bristol-myers-squibb-idUSFWN1Q211V",
    "ord_in_thread": 0,
    "title": "BRIEF-Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Sirenas-\n* SIRENAS ENTERS INTO MULTI-TARGET COLLABORATION WITH BRISTOL-MYERS SQUIBB\n* ‍SIRENAS SAYS CO WILL RECEIVE AN UNDISCLOSED UP-FRONT PAYMENT, FUNDING FOR RESEARCH ACTIVITIES AND POTENTIAL SUCCESS FEES FROM BRISTOL-MYERS SQUIBB​\n* ‍BRISTOL-MYERS HAS OPTION TO LICENSE COMPOUNDS IDENTIFIED FROM COLLABORATIVE EFFORTS UNDER A SEPARATE AGREEMENT\n* ENTERED INTO AGREEMENT WITH BRISTOL-MYERS SQUIBB TO DEPLOY CO‘S DRUG DISCOVERY PLATFORM TO IDENTIFY POTENTIAL DRUG CANDIDATES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-12T21:21:00.000+02:00",
    "crawled": "2018-02-13T15:33:56.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sirenas",
        "enters",
        "collaboration",
        "squibb",
        "say",
        "co",
        "receive",
        "undisclosed",
        "payment",
        "funding",
        "research",
        "activity",
        "potential",
        "success",
        "fee",
        "option",
        "license",
        "compound",
        "identified",
        "collaborative",
        "effort",
        "separate",
        "agreement",
        "entered",
        "agreement",
        "squibb",
        "deploy",
        "co",
        "drug",
        "discovery",
        "platform",
        "identify",
        "potential",
        "drug",
        "candidate",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}